Discovery and Development of an Efficient, Scalable, and Robust Route to the Novel CENP-E Inhibitor GSK923295A

详细信息    查看全文

• 作者：Richard Bellingham ; A. Mark Buswell ; Bernie M. Choudary ; Andrew H. Gordon ; Steve O. Moore ; Matthew Peterson ; Mike Sasse ; Amin Shamji ; Michael W. J. Urquhart
• 刊名：Organic Process Research & Development
• 出版年：2010
• 出版时间：September 17, 2010
• 年：2010
• 卷：14
• 期：5
• 页码：1254-1263
• 全文大小：346K
• 年卷期：v.14,no.5(September 17, 2010)
• ISSN：1520-586X

文摘

The discovery and development of an efficient manufacturing route to the CENP-E inhibitor 3-chloro-N-{(1S)-2-[(N,N-dimethylglycyl)amino]-1-[(4-{8-[(1S)-1-hydroxyethyl]imidazo[1,2-a]pyridin-2-yl}phenyl)methyl]ethyl}−4-[(1-methylethyl)oxy]benzamide (GSK923295A) is described. The existing route to GSK923295A was expensive, nonrobust, used nonideal reagents, and consistently struggled to deliver the API needed for clinical studies. The new synthesis commences from the readily available l-phenylalaninol, which is smoothly converted through to GSK923295A using key Friedel−Crafts acylation as well as selective acylation chemistries. Downstream chemistry to GSK923295A is both high yielding and robust, and the resulting process has been demonstrated first on the kilo scale and subsequently in the pilot plant where 55 kg was successfully prepared. The resulting process is simple, uses cheaper raw materials, is greener in that it avoids using aluminum, tin, and bromination chemistries, and obviates the need for chromatographic purification. Also discussed are the route derived impurities, how they were unambiguously prepared to confirm structure and processing amendments to control their formation, and enhancements to the new process to facilitate future processing.